About Us


In December 2016, CMC Biologics announced that all of its shares were being acquired by AGC Asahi Glass (AGC), a Japanese-based manufacturer of glass, chemicals and high-tech materials. 

AGC Biologics was founded in January 2018 in Bothell, Washington, U.S.A., as a convergence of Asahi Glass Company (AGC) Bioscience, Biomeva GmbH (Heidelberg, Germany), and CMC Biologics to form a global CDMO focused on offering microbial and mammalian capabilities, fulfilling early-phase through late-phase projects and into routine commercial production, both at small and large-scale.

AGC Biologics has since acquired additional facilities and companies around the world, expanding its offerings and creating a strong global network of manufacturing sites stretching across three continents.

Today, the company provides world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells.

The AGC Biologics  global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Bothell, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan.